Shots:

• The P-III IMMhance study results involves assessing of Skyrizi (SC- 150mg) vs PBO in patients in a ratio (4:1) for moderate to severe plaque psoriasis for 2yrs.
• The P-III IMMhance study results: @94wk. complete skin clearance; sPGA 0 (73%); PASI 100 (72%); @16wks. met 1EPs of the first phase of the study; @52wks. met 1EPs of the second phase of the study; sPGA 0 and PASI 100- @55 & 94wks. (65% and 64% & 73% and 72%); @2yrs (81% and 78% vs 7% and 4%) re-randomized to withdrawal patients respectively
• Skyrizi is an IgG1 mAb targeting IL-23- inhibiting its binding with p19 subunit and has received EU’s approval for moderate to severe plaque psoriasis in adults who are candidates for systemic therapy

Ref: Abbvie | Image: AbbVie